Wyndham H. Wilson
Distinguished in Mediastinal Tumor

Dr. Wyndham H. Wilson

Oncology
Bethesda, MD 
Clinical Trials:Currently Recruiting for 2 Trials
45 Years of Experience
Distinguished in Mediastinal Tumor
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson has been practicing medicine for over 45 years and is rated as a Distinguished provider by MediFind in the treatment of Mediastinal Tumor. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

His clinical research consists of co-authoring 163 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Mediastinal Tumor.

Specialties
Oncology
Licenses
Internal Medicine in WV
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Enrollment Status: Recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological
Study Drugs: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid
Study Phase: Phase 1/Phase 2
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Study Phase: Phase 1
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Diagnostic test, Drug, Other, Procedure, Biological
Study Drugs: EPOCH, Rituximab
Study Phase: Phase 2
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Biological, Diagnostic test, Drug, Procedure
Study Drugs: IFN-Alpha, Rituximab, EPOCH
Study Phase: Phase 2
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Rituximab, filgrastim, EPOCH
Study Phase: Phase 2
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug, Other
Study Drug: Ruxolitinib Phosphate
Study Phase: Phase 2
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Biological, Drug
Study Drugs: EPOCH-R, GM-CSF, Idiotype Vaccine
Study Phase: Phase 2
View 6 Less Clinical Trials

163 Total Publications

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Similar Doctors
Kieron M. Dunleavy
Distinguished in Mediastinal Tumor
Dr. Kieron M. Dunleavy
Oncology | Hematology
Distinguished in Mediastinal Tumor
Dr. Kieron M. Dunleavy
Oncology | Hematology

Regional Cancer Care Associates LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (5.0 miles away)
202-444-3736
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kieron Dunleavy is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Dunleavy is rated as an Elite provider by MediFind in the treatment of Mediastinal Tumor. His top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration. Dr. Dunleavy is currently accepting new patients.

Advanced in Mediastinal Tumor
Dr. Sadaf Taimur
Hematology Oncology | Hematology | Oncology
Advanced in Mediastinal Tumor
Dr. Sadaf Taimur
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

7704 Matapeake Business Dr, Suite 200, 
Brandywine, MD 
 (24.3 miles away)
301-812-3900
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sadaf Taimur is a Hematologist Oncology specialist and a Hematologist in Brandywine, Maryland. Dr. Taimur is rated as a Distinguished provider by MediFind in the treatment of Mediastinal Tumor. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Pulmonary Embolism. Dr. Taimur is currently accepting new patients.

Tejaswi R. Sastry
Advanced in Mediastinal Tumor
Dr. Tejaswi R. Sastry
Hematology | Hematology Oncology | Oncology
Advanced in Mediastinal Tumor
Dr. Tejaswi R. Sastry
Hematology | Hematology Oncology | Oncology

Maryland Oncology Hematology

Columbia, MD 
 (19.6 miles away)
410-964-2212
Languages Spoken:
English, Kannada
See accepted insurances

Learn more at marylandoncology.com. Dr. Sastry is rated as a Distinguished provider by MediFind in the treatment of Mediastinal Tumor. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilson's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile